



**Imagion Biosystems
Limited (ASX:IBX) -**

**AGM PRESENTATION
28TH MAY 2021**

www.imagionbiosystems.com

ersonal use only

Imagion Biosystems – at a glance



New medical imaging technologies for the early detection of cancer

Imagion Biosystems ASX:IBX

Australian Medical Device Company developing bio-safe medical imaging technologies.

Market cap: ~\$135.3 million

Cash at 31 Mar 2021: \$13.007 million

R&D operations: San Diego

Registered office: Melbourne

Recent Milestones:

May 2021

First patient enrolled in Phase I breast cancer study

Apr 2021

Brain cancer collaboration with Patrys

Mar 2021

CSIRO Grant to fund prostate cancer collaboration with Monash University

Nov 2020

\$6 million placement

Oct 2020

HREC approval received for Phase I Study


May 2020

Research Collaboration with Siemens

July 2019

Received “**Breakthrough Device**” designation by U.S. FDA

- Innovative **medical imaging** using **magnetic nanoparticles** to identify and stage cancer early
- **Proprietary** MagSense® technology is **non-invasive** and provides more specific & sensitive detection for cancer than current imaging technologies
- **Multiple commercial opportunities:**
 - Proprietary MagSense® imaging technology
 - Magnetic Resonance Imaging (MRI) contrast agent
 - Therapy and/or drug delivery
- MagSense® technology **complements existing imaging** and is more cost effective than many existing imaging technologies
- **First-in-human** studies initiated in Dec 2020 – targeting metastatic breast cancer



Patents are already issued, or are pending, in all the major markets, making the lions share of the global markets available for commercialization.

Patents are valid through 2029.

MagSense® - A new approach to medical imaging



Imagion's technology will transform cancer diagnosis

- **Non-invasive** – a safe and non-surgical solution to detect cancer
- **No radioactivity** - uses bio-safe magnetic nanoparticles to “tag” cancer cells
- **Platform technology** – can be used for many cancers as well as other diseases, *e.g.* infection and cardiovascular
- **Proprietary** - patents issued in most major global markets
- **Breakthrough** - technical feasibility and safety profile vetted, designated as a “Breakthrough Device” by FDA
- **First indication** – metastatic breast cancer, provides shortest path to commercialization
- **First-in-human** – initiated first clinical study - a catalyst for valuation and partnering




Clear unmet medical need

50 years since last new imaging technology was introduced



**X-RAY
(MAMMOGRAPHY)
1913**

- Best used for finding structural anomalies (e.g. broken bones), and chest X-rays
- Mammography used for screening for breast cancer
- Risks include exposure to carcinogenic ionizing radiation




**ULTRASOUND
1956**

- Inexpensive and fast method to look at human organs and areas of inflammation
- Used to guide needle biopsies and detect ovarian cancer
- Poor sensitivity to detecting tumors – tumours must be billions of cells in size



**MAGNETIC RESONANCE (MRI)
1971**

- Best for imaging soft tissue including ligaments, tendons, the brain, and many internal organs
- Used for detecting brain cancers
- Scans can be long and claustrophobic



**COMPUTED TOMOGRAPHY (CT)
1972**

- Better for imaging the lungs than MRI
- Scan times shorter than MRI
- Used in staging solid tumors, guiding biopsy
- Exposes patients to carcinogenic ionizing radiation



**POSITRON EMISSION TOMOGRAPHY (PET)
1973**

- Can be expensive and poorer resolution than MRI or CT
- Better sensitivity for identification of metastatic lesions
- Subject to significant off-target and high background signals
- Requires use of radioactive tracer exposing patients to radiation

“Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor.”

Journal of Clinical Oncology, 2008 New Technologies for Human Cancer Imaging Vol 26 No 24

Broad Commercial Applicability


May be used for many types of cancer and at multiple stages of diagnosis



MAGSENSE® NANOPARTICLES

- Are bio-functionalized to ensure high specificity for targeting different types of cancers, or other diseases.
- Can be used at multiple stages including primary diagnosis, staging, and monitoring the effectiveness of therapy.
- Are compatible with Imagion's proprietary MagSense® technology and with existing installed MRI systems as an MRI contrast agent.
- Uses known safe materials, including iron-oxide cores which are already cleared for multiple clinical uses including therapeutic applications.

MULTIPLE CLINICAL TARGETS



2020-2021 Key Achievements



MagSense® enters the clinic

- HREC approval for Phase I study in Australia
- Collaboration with Siemens Healthineers adds exploration of MRI utility
- MagSense® imaging agent manufacturing for study completed
- Monash Health signed as first clinical site
- Study open for enrolment in Dec 2020
- ***First patient enrolled***

Technology pipeline advancements

- University of Sydney research demonstrates utility of IBX nanoparticles with ultra-low field magnetic resonance imaging (ULF MRI)
- Boston University collaboration explores next generation magnetic sensors to enable doctor's office platform
- \$50k CSIRO grant kick-starts prostate cancer research with Monash University
- Collaboration with Patrys (ASX.PAB) targets brain tumour imaging



Corporate Milestones

- \$14.8 million funds raised
- \$2.2 million R&D Tax Refund
- Appointment of Dianne Angus to Board of Directors
- Appointment of Geoff Hollis as CFO and Company Secretary (based in Melbourne)

Study Update

A first-in-human study of a targeted MagSense® imaging agent

PHASE I
INVESTIGATIONAL STUDY OF A
NOVEL IMAGING AGENT FOR NODAL STAGING OF
**HER2 BREAST
CANCER**



01

- **First Patient enrolled**
- Multiple sites actively screening patients
- Study aims to assess safety, tolerability, and potential effectiveness of the MagSense® imaging agent

02

- Added Clinical Operations personnel in Australia
- Expanding clinical sites nationally to access more patients
- Creating awareness communication campaigns for patients and doctors

03

- Expect a total of ~ 15 patients to be enrolled
- Aim to complete enrolment in 2021 based on patient availability and number of sites

A platform for growth

Significant potential opportunities in biomedical applications of magnetic nanoparticles as results develop




CANCER SCREENING

Magnetic nanoparticles are used to collect/separate tumor cells and cancer DNA from blood



DIAGNOSTIC IMAGING


MagSense® nanoparticles are used for diagnosis and staging of cancers



- Breast Cancer
- Brain Cancer
- Prostate Cancer
- Ovarian Cancer

TREATMENTS

Magnetic nanoparticles can be used for treatment by hyperthermia or used as an adjuvant to deliver cancer drugs or vaccines



Pre-Clinical Initiatives

Expanding MagSense® technology towards the diagnosis of other important cancers

Prostate Cancer



- IBX received \$50,000 CSIRO Federal Government Grant for prostate cancer project.
- Preclinical research project with Monash University's Biomedicine Discovery Institute with the aim of achieving an early proof of concept validation of MagSense® as a prostate cancer imaging agent

Brain Cancer

- Collaboration with Patrys Limited (ASX.PAB)
- Research program aims to pair the targeting capabilities of Patrys' deoxymabs with the imaging capabilities of MagSense® technology to provide a highly effective imaging agent for hard-to-diagnose cancers such as brain cancer.



"Prostate cancer imaging is an evolving field. Imagon's new imaging technology would allow precision mapping of the lymph nodes, identifying smaller foci of cancer that current imaging modalities are unable to identify."

PROFESSOR LISA HORVATH
SCIENTIFIC ADVISORY BOARD MEMBER

"We are very excited to be further leveraging the cancer-targeting ability deoxymabs by partnering with Imagon and its innovative MagSense® imaging technology to potentially develop new ways to visualize and diagnose cancer."


patrys

DR JAMES CAMPBELL
CEO AND MANAGING DIRECTOR



A Path to Growth and Value

Strategic plan provides path to future products and shareholder value



STAGING BREAST CANCER

Reduce unnecessary surgery.
Addressable Market:
\$700 million



TUMOR DETECTION

Breast, prostate, lung & ovarian.
Addressable Market:
\$7 billion



MRI CONTRAST

Safer alternative to current product, Gadolinium.
Addressable Market:
>\$3 billion




TREATMENT MONITORING

Monitor tumor size and adjust treatment accordingly.
Addressable Market:
>\$2 billion



DOCTORS OFFICE

Hand-held MagSense[®] instrument.
Addressable Market:
>\$14 billion



DETECTION & THERAPY

Provide both detection & delivery of therapy.
Addressable Market:
>\$140 billion

Capital Structure

Well funded throughout 2021 into 2022



- 2021 cash flows funded by cash reserves, exercise of listed options and R&D tax incentive
- Increasing cash inflows from exercise of listed options with \$1.3 million received in Q1 2021
- Widely held register with strong relative liquidity

Ordinary shares on issue	1,041 million
Listed and unlisted options (26 May 2021)	353 million
Share price (26 May 2021)	\$0.13
12-month range	\$0.025 - \$0.225
Average daily volume (12 months to 26 May 2021)	11.1 million shares
Market capitalization (26 May 2021)	\$135.3 million
Cash (31 March 2021)	\$13.0 million
Listed options exercised (Jan-Mar 2021)	\$1.3 million
Shareholder data (26 May 2021)	Top 20 shareholders own 20.7%

Backed by strong industry and clinical experience



BOARD OF DIRECTORS



ROBERT PROULX
Chairman & CEO



MICHAEL HARSH
Non-Exec Director



JOVANKA NAUMOSKA
Non-Exec Director



DAVID LUDVIGSON
Non-Exec Director



DIANNE ANGUS
Non-Exec Director



MARK VAN ASTEN
Non-Exec Director

SCIENTIFIC ADVISORS



DR JOHN HAZLE
MD Anderson Cancer
Center



PROF LISA HORVARTH
Chris O'Brien Lifehouse



DR PAUL GRINT
Cardea Bio



DR ROBERT IVKOV
Johns Hopkins Univ



PROF ANDREW SCOTT
AM ONJRC
Austin Hospital

DISCLAIMER



*This investor presentation (**Presentation**) has been prepared by Imagion Biosystems Limited (**Imagion** or the **Company**). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.*

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.

IMAGION[®]

BIO SYSTEMS

Contact:

www.imagionbiosystems.com

info@imagionbio.com

ASX: IBX